Psychiatry AtlasMedication guide · United States

Nonstimulant ADHD medicine

Atomoxetine (Strattera)

Generic name
atomoxetine (as atomoxetine hydrochloride)
Brand names
Strattera
Medication class
Nonstimulant ADHD medicine
Forms covered
atomoxetine hydrochloride oral capsules

Article updated: 2026-10-24 · Sources last checked: 2026-11-05

Medication Safety Alerts

Look-alike / sound-alike name

FDA Boxed Warning

atomoxetine hydrochloride oral capsules.

Atomoxetine increased suicidal ideation in short-term studies of children aged 6 years and older and adolescents with ADHD. Monitor pediatric patients closely for suicidal thoughts or behavior, worsening symptoms and unusual behavioral changes, especially early in treatment or after dose changes. Report these changes promptly to the prescriber.

Atomoxetine treats ADHD in adults and children aged 6 and older. It is a nonstimulant option and is not approved as a depression treatment.

Strattera (discontinued brand).

What to expect: Some improvement may begin in the first week, but fuller benefit can take up to a month.

Warning signs
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Attention-deficit/hyperactivity disorder (ADHD) — Adults and children aged 6 years and older. Part of a broader treatment program that may include psychological, educational and social measures. It is not approved for depression.atomoxetine hydrochloride oral capsules.

Read more: ADHD.

What should I expect?

Some improvement may begin in the first week, but fuller benefit can take up to a month. Follow attention, impulsivity, and daily functioning over time rather than expecting the same day-by-day experience as a stimulant.

Agree on a follow-up plan when treatment starts. Contact the prescriber if symptoms worsen, side effects disrupt daily life, or there is no useful improvement by the planned review; do not change the dose yourself.

How do I take it safely?

Swallow capsules whole with or without food; do not open them. The prescribed schedule may be once in the morning or divided between morning and later in the day. If capsule contents contact the eyes, rinse with water and obtain medical advice.

Keep pulse and blood-pressure checks, including after dose changes; children also need growth and behavior monitoring. Liver problems, known slow metabolism, or interacting medicines can change how treatment is introduced.

MAOI use or failure to allow the required 14-day interval when switching in either direction. Narrow-angle glaucoma; pheochromocytoma or a history of that tumor. Severe cardiovascular disorders likely to worsen with clinically important increases in pulse or blood pressure, or allergy to ingredients.

Review bipolar episodes, urinary retention, and any new hallucinations or unusual mood elevation with the prescriber.

Fluoxetine, paroxetine and other strong CYP2D6 inhibitors increase atomoxetine exposure and change the permitted titration interval. MAO inhibitors must not be combined. Blood-pressure medicines, medicines that raise blood pressure and albuterol or other beta-2 agonists require review and may need closer pulse or blood-pressure monitoring. A pharmacist should check the full medicine list.

Available pregnancy studies are insufficient to establish the medication’s risk; discuss treatment benefits and alternatives with the clinician. The current reference label states that human milk and infant-effect data are lacking, so breastfeeding requires a benefit–risk discussion rather than an assumption of safety.

Safety and effectiveness below age 6 are not established. Children need growth and behavior monitoring. Geriatric safety and effectiveness have not been established, and older adults may have additional cardiovascular or medication-interaction concerns.

The current label says to take a missed dose as soon as possible without exceeding the prescribed total daily amount in any 24-hour period. Ask the pharmacist when timing is uncertain. Atomoxetine does not require a taper according to its label, but planned stopping should still be discussed so ADHD symptoms and any adverse effects can be reviewed.

What side effects should I know about?

  • Nausea, abdominal discomfort, lower appetite, tiredness or sleepiness.
  • Dry mouth, constipation, dizziness and sexual or urinary side effects, particularly in adults.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • New suicidal thoughts or marked behavioral changes need prompt help; immediate danger requires emergency care.
  • Yellow skin or eyes, dark urine, itching or unexplained upper abdominal pain may signal liver injury.
  • Chest pain, fainting, severe allergic swelling or a prolonged painful erection need urgent assessment.

What else should I know to stay safe?

  • Do not use with an MAOI without the required 14-day interval in either direction, after a product allergy, with narrow-angle glaucoma, or with a current or past pheochromocytoma tumor. Severe cardiovascular conditions that could worsen with higher pulse or blood pressure also rule out use under the label.
  • Measure pulse and blood pressure before treatment, after increases, and periodically; children need growth and behavior monitoring. Review bipolar episodes, liver impairment, urinary retention, and interacting medicines such as fluoxetine, paroxetine, blood-pressure drugs, and albuterol. Slow metabolism can change the treatment plan. Do not open capsules because their contents can irritate the eyes.
  • Discuss pregnancy, breastfeeding, and planned stopping with the prescriber. The label does not require a taper, but symptom control and adverse effects still need review. Evidence is insufficient below age 6 and in older adults, and human lactation information is limited.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • Not being a stimulant does not mean that pulse and blood-pressure checks are unnecessary. Atomoxetine can affect both.
  • Do not open a capsule to make it easier to take. Its contents can irritate the eyes; ask the pharmacist about swallowing difficulties.

How does it work?

Atomoxetine reduces the return of norepinephrine, a chemical messenger, into nerve cells after it has been released. This allows more of the messenger to remain available between cells. Researchers do not yet fully understand how this action leads to improvement in attention-deficit/hyperactivity disorder (ADHD) symptoms.

Explore medication science

How was this medicine developed?

The FDA approved Strattera in 2002, adding a nonstimulant approach to ADHD treatment. Its safety information emphasizes mood and behavior in younger patients, liver injury, and heart and blood-pressure effects. The current reference label also addresses differences in how people break the medicine down.

How do I say the name?

Atomoxetine: AT-oh-mox-eh-teen. Capital letters show the stressed syllable.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. Atomoxetine / Strattera: current reference-product labeling
  2. Atomoxetine: patient information
  3. Strattera: FDA approval history and discontinued product record
  4. Atomoxetine / Strattera: FDA prescribing information, June 2026
  5. Atomoxetine: Package Insert / Prescribing Information / MOA
  6. DailyMed - ATOMOXETINE capsule
  7. FDA determination: Strattera was not withdrawn for safety or effectiveness
  8. Generic atomoxetine capsules: product labeling
  9. ISMP List of Confused Drug Names
  10. Schizophrenia
  11. NIMH: Understanding psychosis

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top